07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Arena, Eisai sales and marketing update

Eisai launched Belviq XR lorcaserin extended release for chronic weight management. The wholesale acquisition cost (WAC) for a 20 mg tablet is $8.04. Belviq is approved in the U.S. as an adjunct to diet and...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA approved an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The companies expect the drug to be available this fall. The approval triggered a $10 million...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA accepted an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The partners did not disclose the PDUFA date. The product is an extended-release formulation of twice-daily...